Search | Clinical Trials Finder

Conditions: Relapsed Solid Tumors, Refractory Solid Tumors
Interventions: Eribulin, Irinotecan, Cefixime; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 13 Years to 30 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Lexington, Kentucky • Dallas, Texas

Conditions: Community Acquired Pneumonia
Interventions: lefamulin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more

Conditions: Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth
Interventions: 0.12% CHX and Essential Oil mouthrinse, 2.6% EDTA and 0.2% EDTA mouth rinse; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sinusitis, Chronic Sinusitis
Interventions: Bacitracin, Nasopore sponge soaked with saline; Drug · Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Appendicitis
Interventions: Piperacillin/Tazobactam, Surgical Treatment; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions: EDP-322; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions: Azacitidine, Lenalidomide, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 65 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more

Conditions: Rectal Cancer
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more

Conditions: Revision Total Knee Arthroplasty, Revision Total Hip Arthroplasty, Acute Blood Loss Anemia
Interventions: Revision Total Knee Arthroplasty (TKA), Revision Total Hip Arthroplasty (THA); Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • New York, New York

Conditions: Clostridium Difficile Diarrhea
Interventions: PBCLN-003, Placebo; Drug
Lead sponsor: Prolacta Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Recurrent Urinary Tract Infection
Interventions: Lactobacillus reuteri DSM 17938, trimethoprim/sulfamethoxazole; Dietary Supplement · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Pregnancy Loss, Unexplained Infertility
Interventions: Uterine ERA and microbiome testing, Oral antibiotics and vaginal probiotics; Diagnostic Test · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Celiac Disease
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions: L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 2,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Rochester, Minnesota • St Louis, Missouri

Conditions: Quadriceps Muscle
Interventions: Cepacol, Tom's Natural Mouthwash; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cystic Fibrosis
Interventions: Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Portland, Oregon

Conditions: Cutaneous Abscess
Interventions: Chlorhexidine gluconate, Mupirocin; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prematurity
Interventions: Oral priming; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 1 Year
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Salivary Duct
Interventions: Postoperative Oral Antibiotics (Clindamycin or Augmentin); Drug
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Chlamydial Infection
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Rochester, New York + 1 more

Conditions: Childhood Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 60 Months
Enrollment: 190,238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Search by objective public record fields.

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Tranexamic Acid in Revision Total Joint Arthroplasty

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

Probiotics for Girls With Recurring Urinary Tract Infections

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

Effect of Antibacterial Mouthwash on Muscle Function in Healthy Young Men and Women

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

Effect of Colostrum on Mucosal Immunity in Very Low Birth Weight (VLBWs) Premature Infants

Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement

A Study of Doxycycline to Treat Chlamydial Infection

Mortality Reduction After Oral Azithromycin: Mortality Study